Pulmonary hypertension phenotypes in patients with systemic sclerosis

Pulmonary hypertension (PH) commonly affects patients with systemic sclerosis (SSc) and is associated with significant morbidity and increased mortality. PH is a heterogenous condition and several different forms can be associated with SSc, including pulmonary arterial hypertension (PAH) resulting f...

Full description

Bibliographic Details
Main Authors: Ashraful Haque, David G. Kiely, Gabor Kovacs, A.A. Roger Thompson, Robin Condliffe
Format: Article
Language:English
Published: European Respiratory Society 2021-08-01
Series:European Respiratory Review
Online Access:http://err.ersjournals.com/content/30/161/210053.full
id doaj-5cb63cfe9d7e4aa68fe8739156b9d557
record_format Article
spelling doaj-5cb63cfe9d7e4aa68fe8739156b9d5572021-09-29T08:56:44ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172021-08-013016110.1183/16000617.0053-20210053-2021Pulmonary hypertension phenotypes in patients with systemic sclerosisAshraful Haque0David G. Kiely1Gabor Kovacs2A.A. Roger Thompson3Robin Condliffe4 Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK Medical University of Graz, Graz, Austria Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK Pulmonary hypertension (PH) commonly affects patients with systemic sclerosis (SSc) and is associated with significant morbidity and increased mortality. PH is a heterogenous condition and several different forms can be associated with SSc, including pulmonary arterial hypertension (PAH) resulting from a pulmonary arterial vasculopathy, PH due to left heart disease and PH due to interstitial lung disease. The incidence of pulmonary veno-occlusive disease is also increased. Accurate and early diagnosis to allow optimal treatment is, therefore, essential. Recent changes to diagnostic haemodynamic criteria at the 6th World Symposium on Pulmonary Hypertension have resulted in therapeutic uncertainty regarding patients with borderline pulmonary haemodynamics. Furthermore, the optimal pulmonary vascular resistance threshold for diagnosing PAH and the role of exercise in identifying early disease require further elucidation. In this article we review the epidemiology, diagnosis, outcomes and treatment of the spectrum of pulmonary vascular phenotypes associated with SSc.http://err.ersjournals.com/content/30/161/210053.full
collection DOAJ
language English
format Article
sources DOAJ
author Ashraful Haque
David G. Kiely
Gabor Kovacs
A.A. Roger Thompson
Robin Condliffe
spellingShingle Ashraful Haque
David G. Kiely
Gabor Kovacs
A.A. Roger Thompson
Robin Condliffe
Pulmonary hypertension phenotypes in patients with systemic sclerosis
European Respiratory Review
author_facet Ashraful Haque
David G. Kiely
Gabor Kovacs
A.A. Roger Thompson
Robin Condliffe
author_sort Ashraful Haque
title Pulmonary hypertension phenotypes in patients with systemic sclerosis
title_short Pulmonary hypertension phenotypes in patients with systemic sclerosis
title_full Pulmonary hypertension phenotypes in patients with systemic sclerosis
title_fullStr Pulmonary hypertension phenotypes in patients with systemic sclerosis
title_full_unstemmed Pulmonary hypertension phenotypes in patients with systemic sclerosis
title_sort pulmonary hypertension phenotypes in patients with systemic sclerosis
publisher European Respiratory Society
series European Respiratory Review
issn 0905-9180
1600-0617
publishDate 2021-08-01
description Pulmonary hypertension (PH) commonly affects patients with systemic sclerosis (SSc) and is associated with significant morbidity and increased mortality. PH is a heterogenous condition and several different forms can be associated with SSc, including pulmonary arterial hypertension (PAH) resulting from a pulmonary arterial vasculopathy, PH due to left heart disease and PH due to interstitial lung disease. The incidence of pulmonary veno-occlusive disease is also increased. Accurate and early diagnosis to allow optimal treatment is, therefore, essential. Recent changes to diagnostic haemodynamic criteria at the 6th World Symposium on Pulmonary Hypertension have resulted in therapeutic uncertainty regarding patients with borderline pulmonary haemodynamics. Furthermore, the optimal pulmonary vascular resistance threshold for diagnosing PAH and the role of exercise in identifying early disease require further elucidation. In this article we review the epidemiology, diagnosis, outcomes and treatment of the spectrum of pulmonary vascular phenotypes associated with SSc.
url http://err.ersjournals.com/content/30/161/210053.full
work_keys_str_mv AT ashrafulhaque pulmonaryhypertensionphenotypesinpatientswithsystemicsclerosis
AT davidgkiely pulmonaryhypertensionphenotypesinpatientswithsystemicsclerosis
AT gaborkovacs pulmonaryhypertensionphenotypesinpatientswithsystemicsclerosis
AT aarogerthompson pulmonaryhypertensionphenotypesinpatientswithsystemicsclerosis
AT robincondliffe pulmonaryhypertensionphenotypesinpatientswithsystemicsclerosis
_version_ 1716864465358553088